症状前遗传风险评估对年龄相关性黄斑变性的价值:Moran AMD遗传检测评估(MAGENTA)研究——一项随机对照试验的研究方案
MAGENTA研究是一项在美国犹他大学John A. Moran眼科中心开展的单中心、前瞻性、双盲、随机对照2期试验,按3:1比例将参与者随机分配至立即披露组与延迟披露组并随访12个月,评估告知AMD遗传风险能否促使症状前个体采取可量化的健康生活方式改变,主要结局为皮肤类胡萝卜素状态变化。
要点
- 研究假设:被告知AMD高遗传风险的症状前个体较低风险或延迟披露者更可能做出可量化的积极生活方式改变。
- 主要结局为皮肤类胡萝卜素状态变化,次要结局为眼部和血清类胡萝卜素状态变化。
- 研究将分析AMD遗传风险与基线眼部及全身类胡萝卜素状态和FLIO的相关性。
核心结论
- MAGENTA研究旨在提供证据说明症状前AMD风险检测能否带来可量化的长期行为与生活方式改变,从而降低日后AMD发病率。
研究设计与样本
- MAGENTA研究为2期、单中心、前瞻性、双盲、随机对照试验,在美国犹他州盐湖城犹他大学John A. Moran眼科中心开展。
- 参与者按3:1分配比例随机进入立即披露组和延迟披露组,随访12个月。
主要发现
- 研究评估皮肤、眼部和血清类胡萝卜素状态以及营养和社会调查。
- 皮肤类胡萝卜素通过共振拉曼光谱和反射光谱评估,眼部类胡萝卜素通过Heidelberg Spectralis自发荧光成像和荧光寿命成像检眼镜(FLIO)测量,血清类胡萝卜素采用高效液相色谱定量。
- 主要结局评估皮肤类胡萝卜素状态对遗传风险披露的反应变化。
- 次要结局检查眼部和血清类胡萝卜素状态对遗传风险披露的反应变化。
- 研究还将分析AMD遗传风险与基线眼部及全身类胡萝卜素状态和FLIO的相关性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Age-related macular degeneration (AMD) is an irreversible blinding eye condition with complex genetic and environmental etiologies. Genetic testing for AMD for previously identified multiple-risk single nucleotide polymorphisms can help determine an individual's future susceptibility. However, such testing has been discouraged until evidence shows that providing such information to symptomatic or pre-symptomatic individuals will alter their disease course. Therefore, we designed this study to investigate whether knowledge of AMD risk could stimulate the adoption of a healthier lifestyle that could lower the incidence of AMD later in life. We hypothesize that pre-symptomatic individuals informed of a high genetic risk of AMD are more likely to make quantifiable, positive lifestyle changes relative to participants informed of lower genetic risk or randomized to deferred disclosure of genetic testing results. METHODS: The Moran AMD Genetic Testing Assessment (MAGENTA) study is a phase 2, single-center, prospective, double-masked, randomized controlled trial conducted at the John A. Moran Eye Center, University of Utah, Salt Lake City, Utah, USA. Participants are randomized by a 3:1 allocation ratio to immediate and deferred disclosure groups and followed for 12 months. Skin, ocular, and serum carotenoid status, as well as nutritional and social surveys, are assessed at study visits. Skin carotenoid assessment is by resonance Raman spectroscopy and reflectance spectroscopy, ocular carotenoids are measured with Heidelberg Spectralis autofluorescence imaging and fluorescence lifetime imaging ophthalmoscopy (FLIO), and serum carotenoids are quantified using high-performance liquid chromatography. The primary outcome evaluates changes in skin carotenoid status in response to genetic risk disclosure. The secondary outcomes examine changes in ocular and serum carotenoid status in response to genetic risk disclosure. Also, we will correlate AMD genetic risk with baseline ocular and systemic carotenoid status and FLIO. DISCUSSION: MAGENTA will provide much-needed evidence on whether pre-symptomatic testing for AMD risk can lead to quantifiable long-term changes in behavior and lifestyle associated with a lower incidence of AMD later in life. Findings from the MAGENTA trial will facilitate the design of a future larger, longer-term, multicenter phase 3 trial that could feature subgroup analysis, expanded measures of lifestyle modification, and potential active nutritional interventions. TRIAL REGISTRATION: ClinicalTrials.gov NCT05265624 . Registered on March 3, 2022.
引用
- Addo EK, Hartnett ME, Bernstein PS, et al. The value of pre-symptomatic genetic risk assessment for age-related macular degeneration: the Moran AMD Genetic Testing Assessment (MAGENTA) study-a study protocol for a randomized controlled trial. Trials. 2023. PMID: 37337222. doi:10.1186/s13063-023-07436-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。